We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Customvis | LSE:CUS | London | Ordinary Share | GB0033220350 | ORD 0.01P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.93 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCUS CustomVis plc 23 November 2009 ? 23 November 2009 CUSTOMVIS PLC ("CustomVis" or "the Group") Sales Update CustomVis (AIM: CUS), the leading developer, manufacturer and distributor of solid state laser systems for the refractive surgical industry is pleased to announce it has signed its second laser sale in Argentina. The contract adheres to the Group's standard payment terms with a deposit being received on signing the contract and subsequent payments over an agreed period of time. Further, CEO, Paul van Saarloos lead a team to the American Academy of Ophthalmology (AAO) in San Francisco at the end of October to demonstrate the Group's products - this conference being the world's largest gathering for the industry. Dr van Saarloos received an unprecedented number of inquiries for the Pulzar Z1 laser, particularly from South America as well as for the Group's new product, RetinaVis, a highly portable digital ophthalmoscope, which was presented to a range of customers and distributors. The Group anticipates announcing distributor agreements soon. Following the recent regulatory approval for the customised refractive eye surgery to treat presbyopia, the Group is pleased to announce that it has already implemented the software upgrade on several Pulzar Z1 lasers and started to receive payments in advance for the presbyopia treatments. Interest has been strong from its other customers and the Board expects further orders to quickly follow for this procedure. Dr van Saarloos commented, "Although the Pulzar Z1 inquiries may or may not lead to future sales, we are delighted that interest into our laser is spreading and that sales of PresBvis, the presbyopia treatment, have commenced so quickly." -ends- For further information, please contact: +---------------------------------------+---------------------------------------+ | CustomVis plc | | +---------------------------------------+---------------------------------------+ | Simon Carroll, Chairman | +61 419 304 906 | | Paul van Saarloos, CEO | +61 410 497 456 | +---------------------------------------+---------------------------------------+ | | | +---------------------------------------+---------------------------------------+ | Merchant John East Securities | +-------------------------------------------------------------------------------+ | David Worlidge | 020 7628 2200 | +---------------------------------------+---------------------------------------+ | | | +---------------------------------------+---------------------------------------+ | Leander PR | | +---------------------------------------+---------------------------------------+ | Christian Taylor-Wilkinson | 07795 168 157 | +---------------------------------------+---------------------------------------+ This information is provided by RNS The company news service from the London Stock Exchange END NRABXLFLKFBBFBV
1 Year Customvis Chart |
1 Month Customvis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions